Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colour Bridge
2024-515553-17-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2024
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of rAAV.hCNGA3 in achromatopsia (ACHM) (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: Contrast sensitivity (Pelli Robson 3 m) at 6 months after treatment. Planned start Jul 2024; status: authorised.
02
Drugs
rAAV.hCNGA3
03
Conditions
achromatopsia (ACHM)
Beyond the preview
Go deeper on 2024-515553-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515553-17-00.